ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2016
At a glance
- Drugs Valaciclovir (Primary) ; Valganciclovir
- Indications Cytomegalovirus infections; Epstein-Barr virus infections
- Focus Therapeutic Use
- 26 May 2015 Planned number of patients changed from 30 to 160 as reported by ClinicalTrials.gov.
- 19 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 19 May 2014 Planned end date changed from 1 Apr 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov.